Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.01% | 167.59 | 0.7% | $1123.19m | |
| PFE | Pfizer Inc. | -1.18% | 49.27 | 0.9% | $913.61m | |
| LLY | Eli Lilly & Co. | 2.11% | 316.85 | 1.1% | $810.94m | |
| ABBV | AbbVie, Inc. | -0.77% | 141.45 | 1.9% | $792.28m | |
| MRK | Merck & Co., Inc. | 0.46% | 91.01 | 0.7% | $787.57m | |
| BMY | Bristol-Myers Squibb Co. | 0.57% | 74.55 | 1.0% | $638.52m | |
| SIGA | SIGA Technologies, Inc. | 1.85% | 24.77 | 0.0% | $466.92m | |
| AZN | AstraZeneca Plc | -0.48% | 66.42 | 1.0% | $364.06m | |
| GBT | Global Blood Therapeutics, Inc. | 0.00% | 67.00 | 5.6% | $344.80m | |
| GSK | GSK Plc | -1.65% | 34.68 | 0.3% | $292.03m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -2.20% | 223.13 | 8.2% | $270.05m | |
| VERU | Veru, Inc. | 6.88% | 23.78 | 0.0% | $243.99m | |
| HZNP | Horizon Therapeutics Plc | -3.67% | 61.73 | 5.4% | $222.09m | |
| CCXI | ChemoCentryx, Inc. | -0.16% | 50.78 | 2.9% | $208.38m | |
| KRTX | Karuna Therapeutics, Inc. | -0.93% | 261.23 | 0.0% | $204.24m |
Company Profile
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.